


What is Claimed:

1. A compound having the structure:



wherein each X is independently CR₁ or N, with the proviso that if one X is N then the remaining X are CR₁;

wherein each R₁ is independently -H, -F, -Cl, -Br, -I, -CN, -NO₂, straight chained or branched C₁-C₇ alkyl or alkyloxy, monofluoroalkyl or polyfluoroalkyl, or C₁-C₇ alkyl-C₃-C₆ cycloalkyl;

wherein each R₂ is independently -H, -F, -Cl, -Br, -I, -CN, -NO₂ or straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein n is an integer from 2 to 6 inclusive;

wherein B is CH₂, CHOH, O or CO;

wherein Y is C or N;

wherein Z is O, S, SO, SO₂, CH₂, CO, COH or null;

and wherein A is phenyl or a five-membered heterocycle, where the phenyl or heterocycle is optionally substituted with three or less R₂;

or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, wherein n is 2 or 3.

3. The compound of claim 2, wherein each R₁ is independently -F, -Cl, straight chained or branched C₁-C₄ alkyl or alkoxy, or C₁-C₄ alkyl-C₃-C₆ cycloalkyl.

4. The compound of claim 3, wherein each R₂ is independently -H, -F, -Cl, or straight chained or branched C₁-C₄ alkyl, monofluoroalkyl or polyfluoroalkyl.


5. The compound of claim 4, wherein X is N.

6. The compound of claim 4, wherein each X is CR₁.
7. The compound of claim 6, wherein A is pyridinyl optionally substituted with three or less R₂.
8. The compound of claim 6, wherein A is thienyl optionally substituted with three or less R₂.
9. The compound of claim 6, wherein A is furanyl optionally substituted with three or less R₂.
10. The compound of claim 6, wherein A is thiazolyl optionally substituted with three or less R₂.
11. The compound of claim 6, wherein A is imidazolyl optionally substituted with three or less R₂.
12. The compound of claim 6, wherein A is pyrazolyl optionally substituted with three or less R₂.
13. The compound of claim 6, wherein A is oxazolyl optionally substituted with three or less R₂.
14. The compound of claim 6, wherein A is triazinyl optionally substituted with three or less R₂.
15. The compound of claim 6, wherein A is phenyl optionally substituted with three or less R₂.
16. The compound of claim 15, wherein Z is S, SO or SO₂.
17. The compound of claim 15, wherein Z is CH₂, CO or COH.
18. The compound of claim 15, wherein Z is O or null.
19. The compound of claim 18, wherein B is CH₂.
20. The compound of claim 19, wherein Z is O.
21. The compound of claim 20, wherein the compound is selected from the group consisting of 5-(2-Phenoxyphenyl)-N-(3-(4-piperidyl)phenyl)pentanamide; N-(4-Methyl-3-(4-piperidyl)phenyl)-5-(2-phenoxyphenyl)pentanamide; N-(4-Fluoro-3-(4-piperidyl)phenyl)-5-(2-phenoxyphenyl)pentanamide; N-(2-Fluoro-5-(4-piperidyl)phenyl)-5-(2-phenoxyphenyl)pentanamide; and N-(2-Fluoro-4-methyl-5-(4-piperidyl)phenyl)-5-(2-phenoxyphenyl)pentanamide.



22. The compound of claim 19, wherein Z is null.

23. The compound of claim 22, wherein the compound is selected from the group consisting of *N*-(4-Methyl-3-(4-piperidyl)phenyl)-5-(4-phenylphenyl)pentanamide; *N*-(2-Fluoro-5-(4-piperidyl)phenyl)-5-(4-phenylphenyl)pentanamide; *N*-(2-Fluoro-4-methyl-5-(4-piperidyl)phenyl)-5-(4-phenylphenyl)pentanamide; and *N*-(4-fluoro-3-(4-piperidyl)phenyl)-5-(4-phenylphenyl)pentanamide.




24. The compound of claim 18, wherein B is CO.

25. The compound of claim 24, wherein Z is null.

26. The compound of claim 25, wherein the compound is selected from the group consisting of *N*-(4-fluoro-3-(4-piperidyl)phenyl)-4-oxo-4-(4-phenylphenyl)butanamide; *N*-(2-fluoro-5-(4-piperidyl)phenyl)-4-oxo-4-(4-phenylphenyl)butanamide; *N*-(4-fluoro-3-(4-piperidyl)phenyl)-5-oxo-5-(4-phenylphenyl)pentanamide; 5-oxo-5-(4-phenylphenyl)-*N*-(3-(4-piperidyl)phenyl)pentanamide; *N*-(4-methyl-3-(4-piperidyl)phenyl)-5-oxo-5-(4-phenylphenyl)pentanamide; *N*-(2-fluoro-5-(4-piperidyl)phenyl)-5-oxo-5-(4-phenylphenyl)pentanamide; and *N*-(2,4-difluoro-5-(4-piperidyl)phenyl)-4-oxo-4-(4-phenylphenyl)butanamide.

:



27. The compound of claim 1, wherein the compound is enantiomerically pure.
28. The compound of claim 1, wherein the compound is diastereomerically pure.
29. A pharmaceutical composition that comprises a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition made by admixing a compound of claim 1 and a pharmaceutically acceptable carrier.
31. A process for making a pharmaceutical composition comprising admixing a compound of claim 1 and a pharmaceutically acceptable carrier.
32. A method of treating a subject suffering from an affective disorder selected from the group consisting of depression, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder and anxiety, comprising administering to the subject a therapeutically effective amount of the compound of claim 1.
33. A method of treating a subject suffering from a urinary disorder selected from the group consisting of urinary incontinence, urge incontinence, urinary frequency, urinary urgency, nocturia and enuresis comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

34. A method of treating a subject suffering from an eating disorder selected from the group consisting of obesity, bulimia, bulimia nervosa and anorexia nervosa comprising administering to the subject a therapeutically effective amount of the compound of claim 1.